The PVT1-MYC duet in cancer

Molecular and Cellular Oncology

Volumn 2, Issue 2, 2015, Pages

  Tseng, Yuen Yi ^a,c   Bagchi, Anindya ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

8q24.21; amplification; breast cancer; copy number gain; HCT116; MDA MB 231; MYC; PVT1; SK BR 3; TCGA

Indexed keywords

EID: 85030127154     PISSN: None     EISSN: 23723556     Source Type: Journal    
DOI: 10.4161/23723556.2014.974467     Document Type: Article

References (10)

1. Huppi K, Pitt J J, Wahlberg B M, Caplen N J. The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front Genet 2012; 3:69; PMID:22558003; http://dx.doi.org/10.3389/fgene.2012.00069
2. Erikson J, Nishikura K, ar-Rushdi A, Finan J, Emanuel B, Lenoir G, Nowell P C, and Croce C M. Translocation of an immunoglobulin kappa locus to a region 3' of an unrearranged c-myc oncogene enhances c-myc transcription. Proc Natl Acad Sci U S A 1983; 80:7581–5; PMID:6424112
3. Tseng Y Y, Moriarity B S, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell T C. et al. PVT1 dependence in cancer with MYC copy-number increase. Nature 2014; 512:82–6; PMID:25043044; http://dx.doi.org/10.1038/nature13311
4. Ramirez-Solis R, Liu, Bradley A. Chromosome engineering in mice. Nature 1995; 378:720–4; PMID:7501018
5. Sears R C. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 2004; 3:1133–7; PMID:15467447
6. Mali P, Yang L, Esvelt K M, Aach J, Guell M., DiCarlo J E, Norville J E, Church G. M. RNA-guided human genome engineering via Cas9. Science 2013; 339:823–6; PMID:23287722; http://dx.doi.org/10.1126/science.1232033
7. Hu X, Feng Y, Zhang D, Zhao S D, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang L P. et al. A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. Cancer Cell 2014; 26:344–57; PMID:25203321; http://dx.doi.org/10.1016/j.ccr.2014.07.009
8. Soucek L, Whitfield J, Martins C P, Finch A J, Murphy D J, Sodir N M, Karnezis A N, Swigart L B, Nasi S, Evan G I. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455:679–83; PMID:18716624; http://dx.doi.org/10.1038/nature07260
9. Darnell J E Jr., Transcription factors as targets for cancer therapy. 2002; Nat Rev Cancer 2, 740–9; PMID:12360277
10. Delmore J E, Issa G C, Lemieux M E, Rahl P B, hi J, Jacobs H M, Kastritis E, Gilpatrick T, Paranal R M, Qi J. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146, 904–17; PMID:21889194; http://dx.doi.org/10.1016/j.cell.2011.08.017